Natriuretic peptides increase β1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition

Cardiovascular Research

Volumn 85, Issue 4, 2010, Pages 763-772

  Qvigstad, Eirik ^a,b   Moltzau, Lise R ^a   Aronsen, Jan Magnus ^a   Nguyen, Cam H T ^a   Hougen, Karina ^a   Sjaastad, Ivar ^a,b   Levy, Finn Olav ^a   Skomedal, Tor ^a   Osnes, Jan Bjørn ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Beta adrenoceptors; Cyclic nucleotides; Heart failure; Natriuretic peptides; Phosphodiesterases

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; CILOSTAMIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; CYCLIC NUCLEOTIDE; LIPOCORTIN 5; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE TYPE C; PHOSPHODIESTERASE III; PHOSPHOLAMBAN; PROPIDIUM IODIDE; TROPONIN I;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; BETA ADRENERGIC STIMULATION; CELL ISOLATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ENZYME INHIBITION; HEART CONTRACTION; HEART FAILURE; HEART LEFT VENTRICLE MUSCLE; HEART MUSCLE; HEART MUSCLE CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOIMMUNOASSAY; RAT; STAINING; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; APOPTOSIS; CYCLIC AMP; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HEART FAILURE; MALE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; PHOSPHODIESTERASE INHIBITORS; QUINOLONES; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA-1; SIGNAL TRANSDUCTION;

EID: 76749132702     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp364     Document Type: Article

References (33)

1. Del RS, Passino C, Maltinti M, Emdin M, Giannessi D. C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity. Eur J Heart Fail 2005;7:1145-1148.
2. Kalra PR, Clague JR, Bolger AP, Anker SD, Poole-Wilson PA, Struthers AD et al. Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 2003;107:571-573.
3. Hart CY, Hahn EL, Meyer DM, Burnett JC Jr, Redfield MM. Differential effects of natriuretic peptides and NO on LV function in heart failure and normal dogs. Am J Physiol Heart Circ Physiol 2001;281:H146-H154.
4. Zhang PL, Mackenzie HS, Totsune K, Troy JL, Brenner BM. Renal effects of high-dose natriuretic peptide receptor blockade in rats with congestive heart failure. Circ Res 1995;77:1240-1245.
5. Kuhn M. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res 2003;93:700-709.
6. Potter LR, bbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006; 27:47-72.
7. Ebihara Y, Karmazyn M. Inhibition of beta-but not alpha 1-mediated adrenergic responses in isolated hearts and cardiomyocytes by nitric oxide and 8-bromo cyclic GMP. Cardiovasc Res 1996;32:622-629.
8. Degerman E, Belfrage P, Manganiello VC. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 1997;272:6823-6826.
9. Ono K, Trautwein W. Potentiation by cyclic GMP of beta-adrenergic effect on Ca2+ current in guinea-pig ventricular cells. J Physiol 1991;443:387-404.
10. Wen JF, Cui X, Jin JY, Kim SM, Kim SZ, Kim SH et al. High and low gain switches for regulation of cAMP efflux concentration: distinct roles for particulate GC-and soluble GC-cGMP-PDE3 signaling in rabbit atria. Circ Res 2004;94:936-943.
11. Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA et al. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phos-phodiesterase type 5. Circulation 2007;115:2159-2167.
12. Bers DM. Cardiac excitation-contraction coupling. Nature 2002;415:198-205.
13. Ding B, Abe J, Wei H, Huang Q, Walsh RA, Molina CA et al. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 2005;111:2469-2476.
14. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res 2003;93:896-906.
15. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007;100: 309-327.
16. Amsallem E, Kasparian C, Haddour G, Boissel JP, Nony P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev 2005;1:CD002230.
17. Sjaastad I, Schiander I, Sjetnan A, Qvigstad E, Bokenes J, Sandnes D et al. Increased contribution of alpha 1-vs. beta-adrenoceptor-mediated inotropic response in rats with congestive heart failure. Acta Physiol Scand 2003;177:449-458.
18. Andersen GO, Skomedal T, Enger M, Fidjeland A, Brattelid T, Levy FO et al. Alpha1-AR-mediated activation of NKCC in rat cardiomyocytes involves ERK-dependent phosphorylation of the cotransporter. Am J Physiol Heart Circ Physiol 2004;286:H1354-H1360.
19. Marchmont RJ, Houslay MD. A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem J 1980;187:381-392.
20. Skomedal T, Grynne B, Osnes JB, Sjetnan AE, Oye I. A radioimmunoassay for cyclic AMP (cAMP) obtained by acetylation of both unlabeled and labeled (3H-cAMP) ligand, or of unlabeled ligand only. Acta Pharmacol Toxicol (Copenh) 1980;46:200-204.
21. Koller KJ, Lowe DG, Bennett GL, Minamino N, Kangawa K, Matsuo H et al. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science 1991;252:120-123.
22. Fischmeister R, Castro L, bi-Gerges A, Rochais F, Vandecasteele G. Species-and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol A Mol Integr Physiol 2005;142:136-143.
23. Dickey DM, Flora DR, Bryan PM, Xu X, Chen Y, Potter LR. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology 2007;148:3518-3522.
24. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR et al. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 2006;98: 226-234.
25. Kirstein M, Rivet-Bastide M, Hatem S, Benardeau A, Mercadier JJ, Fischmeister R. Nitric oxide regulates the calcium current in isolated human atrial myocytes. J Clin Invest 1995;95:794-802.
26. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A et al. Phos-phodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007;116:238-248.
27. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A et al. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 2004;95:67-75.
28. Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC. Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest 1991;88:15-19.
29. Castro LR, Verde I, Cooper DM, Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 2006;113:2221-2228.
30. Del RS, Maltinti M, Cabiati M, Emdin M, Giannessi D, Morales MA. C-type natriuretic peptide and its relation to non-invasive indices of left ventricular function in patients with chronic heart failure. Peptides 2008;29:79-82.
31. Jain P, Brown EJ Jr, Langenback EG, Raeder E, Lillis O, Halpern J et al. Effects of milrinone on left ventricular remodeling after acute myocardial infarction. Circulation 1991;84:796-804.
32. Sweet CS, Ludden CT, StabilitoII, Emmert SE, Heyse JF. Beneficial effects of milri-none and enalapril on long-term survival of rats with healed myocardial infarction. Eur J Pharmacol 1988;147:29-37.
33. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-253.